CTLA4 and neoplasm: We observed that 2153L tumors were completely resistant to CTLA-4 and PD-1 blockade, but the combination with zotatifin sensitized this immune-cold tumor model to ICBs and enhanced survival compared with monotherapy (Figure 2, J and K).